Relmada Therapeutics's total assets for Q3 2025 were $14.88M, a decrease of -29.55% from the previous quarter. RLMD total liabilities were $5.41M for the fiscal quarter, a 4.72% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.